REVIEW PAPER
Pharmacological therapy of osteoporosis with bisphosphonates – for whom, what kind, and for how long?
Submission date: 2014-02-11
Final revision date: 2014-05-12
Acceptance date: 2014-07-23
Online publication date: 2014-09-12
Publication date: 2014-08-31
Reumatologia 2014;52(4):238-246
KEYWORDS
TOPICS
ABSTRACT
For many years bisphosphonates (BS) have played an important role in the treatment of postmenopausal osteoporosis. Additionally, they have recently been used in men and induced osteoporosis by administering glucocorticoids and some other secondary osteoporosis. Designing pharmacologically equivalent BS substance administered orally once a week or once a month allowed to reduce side effects related to the digestive system. Availability of intravenous BS substance resulted in a more frequent occurrence of the acute phase reactions. Recently a relation has been noticed between the use of BS and the occurrence of complications including osteonecrosis of the jaw and atypical subtrochanteric fractures. In this article the authors present current knowledge regarding BS treatment in osteoporosis and some adverse effects related to its long-term use. This information will help to optimize the length of treatment with BS and to make a decision about potential discontinuation of BS treatment.
REFERENCES (33)
1.
Kanis JA, Burlet N, Cooper C, et al.; European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013; 19: 399-428. .
2.
Głuszko P, Lorenc R. Osteoporoza pierwotna i wtórna. Wskazówki postępowania dla reumatologów. Reumatologia 2012; 50: 370-377. .
3.
Marcinowska-Suchowierska E, Czerwiński E, Badurski J. Leczenie farmakologiczne osteoporozy. In: Osteoartrologia kliniczna. Badurski J (ed.). Termedia, Poznań 2011; 147-175. .
4.
Body JJ, Bergmann P, Boonen S, et al. Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int 2010; 21: 1657-1680. .
5.
Dziedzic-Gocławska A, Kamiński A. Mechanizmy działania bisfosfonianów na komórki tkanki kostnej. Terapia 2001; 11: 23-27. .
6.
Kavenagh KL, Guo K, Dunford JE, et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A 2006; 103: 7829-7834. .
7.
Drake TD, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008; 83: 1032-1045. .
8.
Miller PD, Jamal SA, Evenepoel P, et al. Renal safety in patients treated with bisphosphonates for osteoporosis: A review. J Bone Miner Res 2013; 28: 2049-2059. .
9.
Hosking D, Chilvers CE, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med 1998; 338: 485-492. .
10.
Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Invention Trial Research Group. Lancet 1996; 348: 1535-1541. .
11.
McClung M, Clemmesen B, Daifotis A, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med 1998; 128: 253-261. .
12.
Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343: 604-610. .
13.
Adachi JD, Saag KG, Delmas PD, et al. Two-year effect of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001; 44: 202-211. .
14.
Schnitzer T, Bone HG, Crepaldi G. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging (Milano) 2000; 12: 1-12. .
15.
Watts NB, Josse RG, Hamdy RC, et al. Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2003; 88: 542-549. .
16.
McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344: 333-340. .
17.
Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002; 71: 103-111. .
18.
Chesnut III CH, Skag A, Christiansen C, et al. Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241-1249. .
19.
Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of oncemonthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006; 65: 654-661. .
20.
Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-1822. .
21.
Lyles KW, Colón-Emeric CS, Magaziner JS, et al. The HORIZON Recurrent Fracture Trial: Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357: 1799-1809. .
22.
Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoprosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009; 373: 1253-1263. .
23.
Rao SS, Budhwar N, Ashfaque A. Osteoporosis in Men. Am Fam Physician 2010; 82: 503-508. .
24.
Ro C, Cooper O. Bisphosphonate drug holiday: choosing appriprate candidates. Curr Osteoporos Rep 2013; 11: 45-51. .
25.
Mc Clung M , Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks and drug holiday. Am J Med 2013; 126: 13-20. .
26.
Suresh E, Paziananas M, Abrahamsen B. Safety issues with bisphosphonate therapy for osteoporosis. Rheumatology (Oxford) 2014; 53: 19-31. .
27.
Rizzoli R, Burlet N, Cahall D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 2008; 42: 841-847. .
28.
Black DM, Kelly MP, et al. Bisphosphonates and fractures of subtrochanteric or diaphyseal femur. N Engl J Med 2010; 362: 1761-1771. .
29.
Shane E, Burr D, Ebrling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of American Society for Bone and Mineral Research. J Bone Miner Res 2010; 11: 2267-2294. .
30.
Giusti A, Hamdy NA, Papapoulos SE, et al. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 2010; 47: 169-180. .
31.
Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stoping alendronate after 5 years of treatment; the Fracture Intervention Trial Long-Term Extension (FLEX): a randomized trial. JAMA 2006; 296: 2927-2938. .
32.
Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zolendronic acid treatment of osteoporosis: a randomized extension to HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012; 27: 243-254. .
33.
Black DM, Bauer DC, Schwartz AV, et al. Continuing Bisphosphonate Treatment for Osteoporosis - For Whom and for How Long? N Engl J Med 2012; 366: 2051-2053.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
